Cord Blood Corporation

Global Cord Blood Corporation, formerly known as China Cord Blood Corporation, is the first and largest umbilical cord blood banking operator in China. The company provides comprehensive cord blood storage services, including the collection, testing, processing, and long-term cryopreservation of stem cells for future medical use. These hematopoietic stem cells are vital for treating over 80 life-threatening diseases, including various forms of leukemia, lymphoma, and genetic blood disorders. Operating through licensed facilities in major regions such as Beijing, Guangdong, and Zhejiang, the company has established a dominant market position in the Chinese healthcare sector. However, following significant corporate governance disputes, the company was placed into provisional liquidation by the Grand Court of the Cayman Islands in 2022.